MicroRNA expression profile in primary lung cancer cells lines obtained by endobronchial ultrasound transbronchial needle aspiration

Guarize, Juliana; Bianchi, Fabrizio; Marino, Elena; Belloni, Elena; Vecchi, Manuela; Donghi, Stefano; Iacono, Giorgio Lo; Casadio, Chiara; Cuttano, Roberto; Barberis, Massimo; Fiore, Pier Paolo Di; Petrella, Francesco; Spaggiari, Lorenzo

doi:10.21037/jtd.2017.12.69

Cited by 10 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LNmets were expanded in cell culture (Fig. 1A) as we previously showed[11]; morphological examination together with immunofluorescence staining using anti-pan-cytokeratin antibody (Pan-CK) confirmed their epithelial origin (Fig. 1B).…”

Section: Resultssupporting

confidence: 69%

miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

Cuttano

Colangelo

Guarize

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Locally-advanced non-small-cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for operable locally-advanced NSCLC (Stage IIIA). However, the majority of patients are NACT-resistant and shows persistent lymph nodal metastases (LNmets) and an adverse outcome. Therefore, the identification of mechanisms and biomarkers of NACT resistance is paramount for ameliorating prognosis of patients with Stage IIIA NSCLC. Here, we investigated the miRNome and transcriptome of chemo naive LNmets collected from patients with Stage IIIA NSCLC (N=64). We found that a microRNA signature accurately predicts NACT response. Mechanistically, we discovered a miR-455-5p/PD-L1 regulatory axis which drives chemotherapy resistance, hallmarks metastases with active IFN-γ response pathway (an inducer of PD-L1 expression), and impacts T cells viability and relative abundances in tumor-microenviroment (TME). Our data provides new biomarkers to predict NACT response and adds molecular insights relevant for improving the management of patients with locally-advanced NSCLC.

show abstract

Section: Resultssupporting

confidence: 69%

miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

Cuttano

Colangelo

Guarize

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Based on our previous expertise, we are developing new applications for EBUS-TBNA such as a new protocol for EBUS-TBNA primary lung cancer cell culture and microRNA profile in stage IIIA (pN2) NSCLC patients, testing the feasibility of a microRNA profile obtained from EBUS-TBNA [ 24 ] and the correlation with the prediction of chemotherapy response. In addition, new molecular analyses are being developed, and the correlation between PDL-1 expression and tumour histology is under evaluation.…”

Section: Discussionmentioning

confidence: 99%

Endobronchial Ultrasound Transbronchial Needle Aspiration in Thoracic Diseases: Much More than Mediastinal Staging

Guarize

Casiraghi

Donghi

et al. 2018

Canadian Respiratory Journal

Self Cite

View full text Add to dashboard Cite

Background and Objective EBUS-TBNA has revolutionized the diagnostic approach to thoracic diseases from a surgical to minimally invasive procedure. In non small-cell lung cancer (NCSLC) patients, EBUS-TBNA is able to dictate the consecutive therapy both for early and advanced stages, providing pathological diagnosis, mediastinal staging, and even adequate specimens for molecular analysis. This study reports on the ability of EBUS-TBNA to make different diagnoses and dictates the consecutive therapy in a large cohort of patients presenting different thoracic diseases. Methods All procedures performed from January 2012 to September 2016 were reviewed. Five groups of patients were created according to the main indications for the procedure. Group 1: lung cancer staging; Group 2: pathological diagnosis in advanced stage lung cancer; Group 3: lymphadenopathy in previous malignancies; Group 4: pulmonary lesions; Group 5: unknown origin lymphadenopathy. In each group, the diagnostic yield of the procedure was analysed. Non malignant diagnosis at EBUS-TBNA was confirmed by a surgical procedure or clinical and radiological follow-up. Results 1891 patients were included in the analysis. Sensitivity, negative predictive value, and diagnostic accuracy in each group were 90.7%, 79.4%, and 93.1% in Group 1; 98.5%, 50%, and 98.5% in Group 2; 92.4%, 85.1%, and 94.7% in Group 3; 90.9%, 51.0%, and 91.7% in Group 4; and 25%, 83.3%, and 84.2% in Group 5. Overall sensitivity, negative predictive value, and accuracy were 91.7%, 78.5%, and 93.6%, respectively. Conclusions EBUS-TBNA is the best approach for invasive mediastinal investigation, confirming its strategic role and high accuracy in thoracic oncology.

show abstract

“…As new technological solutions are developing to improve diagnostics, the number of novel promising cancer-related markers also increases and one of these is microRNAs. MicroRNA are small, single-stranded non-coding RNA, with length of 19-25 nucleotides, which are present in biological fluids (blood, plasma, saliva, and urine) and can be tested in formalin-fixed paraffin-embedded and in fresh tissue biopsies (Freitas et al, 2021;Guarize et al, 2018;Wu et al, 2019). Recent studies showed that miRNAs play a role in the tumorigenesis by regulating the cell cycle, angiogenesis, metabolism, proliferation, metastasis, apoptosis, and gene expression via post-transcriptional regulation of mRNA.…”

Section: Micrornamentioning

confidence: 99%

Liquid Biopsy — A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer

Mikilps-Mikgelbs

Pupola

Antone

et al. 2022

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality worldwide. Early diagnosis of lung cancer is hampered by the absence of specific symptoms and the lack of a widely recognised cost-effective screening programme. Acquisition of a tumour tissue sample for morphological and molecular genetic examination is of paramount importance for cancer diagnosis. We describe diagnostic challenges for early-stage lung cancer and their possible current solutions. Liquid biopsy is a relatively new technology that was developed for evaluation of tumour-related circulating genetic material. Recent achievements in data processing provide more opportunities for wider implementation of Next Generation Sequencing (NGS) in clinical practice. This article summarises available data on the current and future role of liquid biopsy in the management of lung cancer. We also present an ongoing Latvian lung cancer study that focuses on integration of liquid biopsy with comprehensive clinical data utilising advantages of information technologies.

show abstract

MicroRNA expression profile in primary lung cancer cells lines obtained by endobronchial ultrasound transbronchial needle aspiration

Abstract: The miRNA expression profile is feasible and reliable in EBUS-TBNA specimens. Validation of this protocol in fresh cytological specimens represents an effective and reproducible method to correlate translational and clinical research.

Cited by 10 publications

References 14 publications

miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

Endobronchial Ultrasound Transbronchial Needle Aspiration in Thoracic Diseases: Much More than Mediastinal Staging

Liquid Biopsy — A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer

Contact Info

Product

Resources

About